📖
COVID-19 Drug Development
DOAB Contributor

COVID-19 Drug Development

Author / Organization:
Open Access Books Published 2023 Verification Pending

Overview & Synopsis

COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences.

Indexed from repository: Directory of Open Access Books (www.doabooks.org)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title COVID-19 Drug Development
Author / Organization DOAB Contributor
Subject & Discipline Other branches of medicine
Categories Open Access Books
Publication Year 2023
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website Directory of Open Access Books (www.doabooks.org)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-130165
Original Source Link Visit Source Page on www.doabooks.org »